The phase 3 trial Checkmate 816, further investigating the use of nivolumab plus chemotherapy versus chemotherapy alone, showed benefits associated with complete pathological response [57] when combination therapy was used for patients with stage II and III NSCLC without EGFR or ALK alterations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.